Form 4: Jasper Therapeutics Director Chris Nolet Receives Automatic Stock Option Grant

Jasper Therapeutics, Inc. Director Chris Nolet was granted 7,500 stock options as part of the company's non-employee director compensation policy.

Summary

• Chris Nolet, a Director of Jasper Therapeutics, Inc. (JSPR), was granted 7,500 stock options.
• The options have an exercise price of $6.77 per share.
• The transaction date for this grant was July 3, 2025.
• The options become exercisable on July 3, 2026, and expire on July 3, 2035.
• This grant was made automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides for an option to purchase 7,500 shares on the date of each annual meeting of stockholders.

Sentiment

Score: 6

Explanation: The document reports a routine, expected insider transaction related to director compensation, which is generally viewed as a neutral to slightly positive event as it aligns director interests with shareholders.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing long-term company performance.

Future Outlook

The document details a routine stock option grant with specific future exercisable and expiration dates, but does not provide broader forward-looking statements or guidance on company performance.

Management Comments

• The stock option grant was made automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders.

Industry Context

The automatic grant of stock options to non-employee directors is a common practice across various industries, particularly in the biotechnology and pharmaceutical sectors, to attract and retain qualified board members and align their incentives with shareholder value.

Comparison to Industry Standards

• Granting stock options to non-employee directors is a standard compensation practice in publicly traded companies, including those in the biotechnology sector like Jasper Therapeutics.
• The specific number of shares (7,500) and the exercise price ($6.77) are determined by the company's compensation policy and market conditions at the time of the grant, consistent with typical equity compensation structures for board members.

Corporate Governance

Related Party Transactions

• The grant of stock options to Chris Nolet, a Director, constitutes a transaction with a related party, executed under the company's established Non-Employee Director Compensation Policy.

Stakeholder Impact

• Shareholders: The grant of options to a director aims to align the director's financial interests with long-term shareholder value creation.

Next Steps

• The options granted to Chris Nolet will become exercisable on July 3, 2026, at which point he may choose to exercise them.

Key Dates

Keywords

Jasper Therapeutics, JSPR, Stock Option, Director Compensation, Insider Transaction, Form 4, Beneficial Ownership